Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17723501 | 1.00 | TRPA1 (0.34) | TRPA1LMNAPDK1PDK2PDK3 | |
| SCHEMBL19604528 | 1.00 | TRPA1 (0.34) | TRPA1LMNAPDK1PDK2PDK3 | |
| Hydrochloric Acid SCHEMBL19583115 | 0.98 | TRPA1 (0.33) | TRPA1LMNAPDK1PDK2PDK3 | |
| SCHEMBL2985427 | 0.86 | LMNA (0.33) | TRPA1LMNA | |
| SCHEMBL13674233 | 0.86 | LMNA (0.33) | TRPA1LMNA | |
| SCHEMBL1543556 | 0.86 | LMNA (0.33) | TRPA1LMNA | |
| SCHEMBL14639220 | 0.86 | LMNA (0.33) | TRPA1LMNA | |
| SCHEMBL14639219 | 0.86 | LMNA (0.33) | TRPA1LMNA | |
| SCHEMBL1543559 | 0.86 | LMNA (0.33) | TRPA1LMNA | |
| SCHEMBL12825387 | 0.86 | LMNA (0.33) | TRPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183866-A1 | 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3180338-B1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INT (DE) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183866-A1 | 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT | PRKAG2, PRKAB2, PRKAG1 | TRPA1 4310/4885LMNA 4279/4885PDK1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.